Findings

What do systematic reviews say?

18 questions · 18 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 22.2%Low 7 · 38.9%Moderate 3 · 16.7%High 4 · 22.2%

Mycophenolate mofetil vs IV cyclophosphamide

Death · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.12 [0.61, 2.06]
8 studies · 826 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

ESKD · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes ESKD compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.71 [0.27, 1.84]
3 studies · 231 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

Complete renal remission · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.17 [0.97, 1.42]
8 studies · 828 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Partial renal remission · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
9 studies · 868 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Ovarian failure · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.36 [0.06, 2.18]
3 studies · 539 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

Major infection · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in major infection compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.54]
6 studies · 699 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Alopecia · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) probably leads to lower alopecia compared with IV cyclophosphamide (CPA) (moderate certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.29 [0.19, 0.46]
3 studies · 622 participants
Moderate

Mycophenolate mofetil vs IV cyclophosphamide

Diarrhoea · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) probably leads to higher diarrhoea compared with IV cyclophosphamide (CPA) (moderate certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 2.42 [1.64, 3.58]
4 studies · 609 participants
Moderate

Mycophenolate mofetil vs azathioprine (AZA)

Death, all cause · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) showed no clear difference in death, all cause compared with azathioprine (AZA) (moderate certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 0.95 [0.7, 1.29]
16 studies · 2987 participants
Moderate

Mycophenolate mofetil vs azathioprine (AZA)

Graft loss censored for death · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) leads to lower graft loss, censored for death compared with azathioprine (AZA) (high certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 0.78 [0.61, 0.98]
17 studies · 2540 participants
High

Mycophenolate mofetil vs azathioprine (AZA)

Malignancy · patients with kidney transplant recipients

It is very uncertain whether mycophenolate mofetil (MMF) changes malignancy, any compared with azathioprine (AZA) (very low certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 0.81 [0.6, 1.09]
5 studies · 1735 participants
Very low

Mycophenolate mofetil vs azathioprine (AZA)

Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 0.48 [0.36, 0.65]
15 studies · 2914 participants
High

Mycophenolate mofetil vs azathioprine (AZA)

Infection, CMV tissue invasive As reported in the articles · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) leads to higher infection, CMV tissue invasive As reported in the articles compared with azathioprine (AZA) (high certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 1.7 [1.1, 2.61]
7 studies · 1510 participants
High

Mycophenolate mofetil vs azathioprine (AZA)

Acute rejection, total Any treated acute rejection, including biopsy‐proven · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) leads to lower acute rejection, total Any treated acute rejection, including… compared with azathioprine (AZA) (high certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 0.65 [0.57, 0.73]
22 studies · 3301 participants
High

Mycophenolate mofetil vs azathioprine (AZA)

Chronic allograft nephropathy Biopsy required in 2 RCTs, one study with optional biopsy · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) may leads to lower chronic allograft nephropathy Biopsy required in 2 RCTs, one study… compared with azathioprine (AZA) (low certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 0.69 [0.48, 0.99]
3 studies · 203 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Partial renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1 [0.78, 1.28]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Stable kidney function · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.78 [1.4, 2.26]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Complete renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 2.38 [1.07, 5.3]
2 studies · 402 participants
Low